Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.71 |
| ▸ | CTSD | P07339 | 8/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CTSE | P14091 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225650 | 0.90 | BACE1 (0.73) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL4887800 | 0.89 | BACE1 (0.71) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL4887753 | 0.89 | BACE1 (0.71) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL5096533 | 0.87 | BACE1 (0.73) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL4890992 | 0.87 | BACE1 (0.68) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL4883545 | 0.86 | BACE1 (0.67) | BACE1CTSDBACE2CTSE | |
| SCHEMBL4892509 | 0.86 | BACE1 (0.67) | BACE1CTSDBACE2KCNH2CTSE | |
| SCHEMBL8223587 | 0.85 | BACE1 (0.71) | BACE1CTSDBACE2 | |
| SCHEMBL4888921 | 0.84 | BACE1 (0.77) | BACE1CTSDBACE2 | |
| SCHEMBL4888095 | 0.84 | BACE1 (0.64) | BACE1CTSDBACE2KCNH2CTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | claimed |
| WO-2007145571-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145569-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007145571-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214577-A1 | New Compounds 320 | PSEN1, PSEN2, MAPT | BACE1 5/4885CTSD 2212/4885BACE2 19/4885 |
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | BACE1 5/4885CTSD 1887/4885BACE2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.